InvestorsHub - NYSE, NASDAQ, AMEX, OTCBB, Pink Sheet Stock Message Boards, Stock Charts, Stock Quotes, Level II and Market News

Ticker	Name	Price	Change	Change %	Volume	Posts
AREB	American Rebel Holdings Inc	19.50	15.54	392.42%	83,206,175	368
AEHL	Antelope Enterprise Holdings Ltd	4.20	2.10	100.00%	11,164,888	54
CXAI	CXApp Inc	1.41	0.6040	74.86%	92,259,155	453
XHG	XChange TED Inc	1.11	0.3700	50.00%	2,994,677	121
WCT	Wellchange Holdings Company Limited	0.2790	0.0840	43.08%	208,108,690	23
SOBR	SOBR Safe Inc	4.93	1.46	42.03%	1,275,545	1,052
MHLD	Maiden Holdings Ltd	0.7948	0.2301	40.75%	630,544	43
FORD	Forward Industries Inc	6.87	1.95	39.63%	546,577	293
RGC	Regencell Bioscience Holdings Ltd	33.20	8.90	36.60%	265,350	407
ICCT	iCoreConnect Inc	5.69	1.46	34.51%	83,114,588	3,664

Ticker	Board Name	Price	Change %	Posts (24h)
TWOH	Two Hands Corp	0.0042	+68.00%	157
LWLG	Lightwave Logic Inc	0.9001	0.00%	62
ELTP	Elite Pharmaceuticals Inc	0.3197	-11.93%	38
COOP	Mr Cooper Group Inc	133.70	+0.45%	26
TGLO	TheGlobe.com Inc	0.3000	-4.00%	7
XRPUSD	Ripple	1.99	-6.57%	13

	Board Name	Posts (24h)
	ORIONS Money Stocks	10
	DD Support Board and Research Team	52
	Savvy Trades and Investments	19
4	BBs Stock Haven	27
5	Billionaire Boys Club Member Forum BBCMF	37
6	Savvy Pick 10 Contest 1	8

Ticker	Name	Price	Change %	Market Cap	Volume ($)
BTC	Bitcoin	78,919.74	-4.99%	1,568.9B	45.2M	Message Board Quote News
USDT	Tether USD	0.9994	-0.02%	141.8B	25.4M	Message Board Quote News
XRP	Ripple	1.99	-6.57%	114.9B	33.4M	Message Board Quote News
USDC	USD Coin	0.9999	0.00%	56.1B	5.1M	Quote News
SOL	Solana	108.47	-9.02%	53.1B	25.3M	Message Board Quote News
ADA	Cardano	0.5883	-9.37%	21.3B	5.9M	Message Board Quote News
TRX	TRON	0.233189	-1.92%	20.1B	69,857	Message Board Quote News
STETH	stETH	1,881.32	0.00%	17.7B	341,723	Quote News
XLM	Stellar Lumens	0.242297	-3.62%	7.4B	4.3M	Message Board Quote News
LINK	ChainLink Token	11.52	-9.08%	7.4B	5.4M	Message Board Quote News

Play Episode

3min

Proactive - Interviews for investors

Nevis Brands doubles revenue in 2024, cuts losses & expands in key Markets

Nevis Brands CEO John Kueber joined Steve Darling from Proactive to discuss the company’s financial results for fiscal year 2024 and the fourth quarter ending November 30, 2024. Nevis reported $1.56 million in revenue, more than doubling its 2023 sales as it expanded into new markets and introduced new cannabis products. The company narrowed its net loss to approximately $362,000, down from $400,000 the previous year. When excluding interest, depreciation, and amortization, the adjusted loss was reduced to about $58,000. Nevis maintained its leading position in Washington’s cannabis beverage market and achieved the second-best sales ranking in Missouri within its first year in that state. The company also made significant progress in debt reduction, cutting current liabilities from $1.12 million to about $573,000 through debt payments and restructuring. Looking ahead to 2025, Nevis expects continued growth driven by expanding sales of its Happy Apple and Major brands in the hemp-derived THC beverage market. The company also looking for market re-entry in Ohio and Arizona following previous licensing and market shifts. All this happening while the company focused on licensing established products in key markets. Kueber acknowledged that the fourth quarter was challenging, with revenue declines due to licensing and market shifts in Arizona, Ohio, Oregon, and California. However, growth in New Jersey and Missouri helped offset these declines, and the company remains focused on long-term expansion and profitability. #proactiveinvestors #nevisbrandsinc #cse #nevi #otcqb #nevif #majorbrand #cannabis #CannabisInvesting #THCDrinks #HappyApple #CannabisStocks #HempTHC #CannabisBeverages #InvestorUpdate #JohnKueber #CannabisNews #CannabisRevenue #DebtReduction #ProactiveInvestors

Proactive - Interviews for investors

Candel Therapeutics shares positive survival data for investigational immunotherapy in NSCLC

Candel Therapeutics CEO Dr. Paul Peter Tak joined Steve Darling from Proactive to announce final survival data from a Phase 2a clinical trial evaluating the company’s investigational immunotherapy in patients with stage III/IV non-small cell lung cancer (NSCLC) who had an inadequate response to immune checkpoint inhibitor (ICI) treatment. The study reported a median overall survival (mOS) of 24.5 months in 46 evaluable patients who received two courses of the investigational therapy. In a subset of patients who had progressive disease at baseline despite ICI treatment, mOS was 21.5 months. Historically, similar patients receiving standard-of-care chemotherapy have had mOS between 9.8 and 11.8 months, with published studies rarely exceeding 12 months. With a median follow-up of 32.4 months, the data demonstrated long-term survival benefits, with 37% of patients who had progressive disease despite ICI therapy still alive two years after treatment. Based on these positive results, Candel Therapeutics will continue advancing the development program, including preparations for a potential registrational trial in patients with non-squamous histology NSCLC. The U.S. Food and Drug Administration (FDA) has previously granted Fast Track Designation for the investigational therapy in combination with an antiviral agent and ICI therapy for patients with stage III/IV NSCLC who are resistant to first-line PD-(L)1 inhibitors and do not have activating molecular driver mutations or have progressed on targeted therapy. These findings support the therapy’s potential as a new treatment option for NSCLC patients with limited alternatives. #proactiveinvestors #candeltherapeuticsinc #nasdaq #cadl #CancerTreatment #ViralTherapy #ProstateCancer #PancreaticCancer #Glioblastoma #PaulPeterTak #ClinicalTrials #BiotechNews #Immunotherapy #Oncology #CancerResearch

Proactive - Interviews for investors

OKYO Pharma achieves key stability milestone for Urcosimod in clinical development

OKYO Pharma CEO Gary Jacob joined Steve Darling from Proactive to share a significant advancement in the company’s ongoing drug development efforts. The company has successfully demonstrated that urcosimod—formerly known as OK-101—remains stable for more than two and a half years in single-use ampoules, which are used for patient administration. This milestone is a crucial step forward in ensuring the long-term viability of the drug as it progresses through clinical trials. Urcosimod is currently being evaluated in a Phase 2b clinical trial, which is a randomized, placebo-controlled, double-masked study involving 48 patients. The trial is focused on assessing the drug’s effectiveness in treating neurotrophic keratopathy (NCP), a serious and progressive degenerative eye disease. Jacob emphasized that achieving success in clinical development extends beyond obtaining positive clinical trial data. A crucial aspect of regulatory approval includes meeting the rigorous Chemistry, Manufacturing, and Controls (CMC) requirements set by the U.S. Food and Drug Administration (FDA). By demonstrating long-term stability, OKYO Pharma has strengthened its regulatory submission package, addressing an essential factor in the drug’s future approval and commercialization. The company recently completed Good Manufacturing Practice (GMP) stability assay testing of single-use ampoules containing urcosimod in an ophthalmic solution. The results were highly promising—ampoules stored under refrigerated conditions maintained stability for over two and a half years, while initial three-month data from samples stored at room temperature showed potency levels at or above 100%. These findings reinforce confidence in urcosimod’s shelf life and its potential for real-world clinical use. As OKYO Pharma continues to advance urcosimod through the regulatory and clinical development process, this stability milestone represents a critical achievement in its journey toward providing an effective tr

Proactive - Interviews for investors

Nextech3D.ai disrupts industry with launch of AI-powered Ecommerce content studio

Nextech3D.ai CEO Evan Gappelberg joined Steve Darling from Proactive to announce the launch of a new AI-powered feature as part of the company’s Ecommerce AI Studio. The platform utilizes generative AI to create photorealistic lifestyle images and videos of products—such as apparel, accessories, and furniture—being worn, held, or displayed in realistic settings, eliminating the need for traditional photography. Gappelberg highlighted that ToggleStudios, Nextech3D.ai’s AI-driven content creation tool, is designed to help online retailers generate lifestyle content at scale. The platform reduces reliance on costly and time-consuming physical photoshoots, enabling faster content production, lower operating costs, and increased visual output. The new feature will allow users to generate AI-rendered images of apparel on virtual models with varied backgrounds and appearances. Additionally, retailers can visualize accessories, electronics, and other items in realistic usage scenarios, enhancing product presentation for e-commerce. Another major upgrade is the automated generation of product videos and interactive 3D visuals. Using advanced AI, the system simulates lighting, texture, and perspective, ensuring high-quality imagery that closely replicates traditional photography—but in less time and at a lower cost. #nextech3d.al #otcqx #nexcf #cse #ntar #EvanGappelberg #AmazonSellerCentral #3DModeling #AIPhotography #EcommerceInnovation #3DTechnology #LifestylePhotography #ProactiveInterviews #TechInnovation #AmazonPartners#proactiveinvestors #nextech3d.al

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Join the InvestorsHub Community

Trade War Concerns Lead To Extended Nosedive On Wall Street

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Join the InvestorsHub Community

Trade War Concerns Lead To Extended Nosedive On Wall Street

Go Ad-Free